As the frequency of Enterobacterales (ENT) producing metallo-β-lactamase (MBL) and/or OXA-48 is increasing in some US medical centers, effective antimicrobials to treat the infections caused by these organisms are urgently needed. Aztreonam-avibactam (ATM-AVI) is under clinical development for treatment of infections caused by Gram-negative bacteria, including MBL producers. We evaluated the activities of ATM-AVI, ceftazidime-avibactam (CAZ-AVI), meropenem-vaborbactam (MEM-VAB), and comparators against ENT isolated from patients with bloodstream infections (BSIs).4,802 ENT were consecutively collected (1/patient) from 72 US medical centers in 2020–2022 and susceptibility tested by CLSI broth microdilution method. ATM-AVI was tested with AVI at a fixed 4 mg/L. A pharmacokinetic/pharmacodynamic susceptible (S) breakpoint of ≤ 8 mg/L was applied for comparison. Carbapenem-resistant ENT (CRE) isolates were screened for carbapenemase (CPE) by whole genome sequencing.E. coli and 1 E. aerogenes (CRE). All CPE producers and 98.0% of CREs were inhibited at an ATM-AVI MIC of ≤ 8 mg/L. CAZ-AVI and MEM-VAB were active against 81.6% and 65.3% of CREs, respectively. Ceftolozane-tazobactam (TOL-TAZ) was active against only 72.6% of ceftriaxone (CRO)-nonsusceptible (NS) isolates. ATM-AVI retained activity  against all MEM-VAB-NS and 90.0% of CAZ-AVI-NS isolates. The most common CPEs were KPC-2/3 (57.1% of CREs), OXA-48–like (16.3%), and NDM (12.2%). A CPE gene was not observed in 14.3% of CREs. CAZ-AVI and MEM-VAB were active against 100.0% of KPC producers, but CAZ-AVI showed limited activity against MBL producers and MEM-VAB showed limited activity against OXA-48–like and MBL producers. The most active comparators against CRE were tigecycline (95.9%S), gentamicin (49.0%S), and amikacin (44.9%S).ATM-AVI was highly active against ENT (Table); only 2 isolates showed ATM-AVI MICs > 8 mg/L: 1 MEM-S ATM-AVI demonstrated potent activity against a large collection ENT isolated from patients with BSI in US hospitals, including CREs and isolates resistant to recently approved β-lactamase inhibitor combinations. These results support further clinical development of ATM-AVI.Helio S. Sader, MD, PhD, FIDSA, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|Cipla: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support Cecilia G. Carvalhaes, MD, PhD, AbbVie: Grant/Research Support|bioMerieux: Grant/Research Support|Cipla: Grant/Research Support|CorMedix: Grant/Research Support|Melinta: Grant/Research Support|Pfizer: Grant/Research Support John H. Kimbrough, PhD, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support Rodrigo E. Mendes, PhD, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|Cipla: Grant/Research Support|Entasis: Grant/Research Support|GSK: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support Mariana Castanheira, PhD, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|bioMerieux: Grant/Research Support|Cipla: Grant/Research Support|CorMedix: Grant/Research Support|Entasis: Grant/Research Support|Melinta: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support


The correct citation is: Rees SJ, Mohsin M, Tay AK, Moussa B, Klein L, Nadar N, et al. (2023) COVID-19 stressors and mental health problems amongst women who arrived as refugees and those born in Australia. PLOS Glob Public Health 3(7): e0002073.


Article title: Antidepressant effects of total iridoids of Valeriana jatamansi via the intestinal flora-blood–brain barrier pathwayAuthors: Zhang, L., Wang, L., Huang, L., Zhao, Y., Ding, H., Li, B., Wen, L., Xiong, W., Liu, Y., Zhang, T., Zhang, L., Wu, L., Xu, Q., Fan, Y., Wei, G., Yin, Q., Chen, Y., Zhang, T., & Yan, Z.Journal:Pharmaceutical BiologyBibliometrics: Volume 59, Number 01, pages 910–919DOI:https://doi.org/10.1080/13880209.2021.1944222In the version of this article initially published, there was a mistake in the images of part labels (A) and (B) of Figure 7.The images of part labels (A) and (B) of Figure 7 are now corrected and the article has been republished online along with a minor correction where the author Zhiyong Yan’s contact details have been added.


Article title: Discovery of novel arylamide derivatives containing piperazine moiety as inhibitors of tubulin polymerization with potent liver cancer inhibitory activityAuthors: Xiao-Yi Shi, Huang Jiao, Jia-Kai Zhang, Xin-Yi Tian, Dan-Feng Guo, Jie Gao, Mei-Qi Jia, Jian Song, Sai-Yang Zhang, Xiang-Jing Fu, Hong-Wei TangJournal:Journal of Enzyme Inhibition and Medicinal ChemistryBibliometrics: Volume 38, Number 1,DOI:https://doi.org/10.1080/14756366.2023.2237701Figure 5A ∼ C of this article. The authors would like to apologize for any inconvenience caused. The correct version of Figure 5 is as follows:The authors regret the following errors in


Updated COVID-19 vaccines have been developed to help broaden protection against circulating SARS-CoV-2 variants. Here we present a 3-month interim analysis from a phase 3, randomized, observer-blind, active-controlled study of 2 omicron BA.1-containing vaccines: BA.1-monovalent mRNA-1273.529 (BA.1 variant only) and BA.1-bivalent mRNA-1273.214 (SARS-CoV-2 Wuhan-Hu-1 strain and BA.1 variant).This multicenter study evaluated safety and immunogenicity of the BA.1-monovalent (Part 1) and -bivalent (Part 2) vaccines in individuals aged ≥ 16 years in the United Kingdom (NCT05249829). Eligible participants previously received 2 or 3 doses of an authorized/approved COVID-19 vaccine and were randomly assigned 1:1 to receive a 50-µg booster of the original mRNA-1273 vaccine or either BA.1-monovalent or -bivalent vaccines. Safety and reactogenicity up to 3 months post-booster were evaluated. Immunogenicity objectives were to demonstrate non-inferiority and/or superiority of BA.1-monovalent or -bivalent vaccine-elicited immune responses to BA.1 and the ancestral strain (D614G) at Day 29 and Month 3 compared with a booster dose of mRNA-1273 in participants without evidence of baseline SARS-CoV-2 infection up to day of analysis visit on Day 29 or Month 3.At the interim analysis, 724 (Part 1) and 2824 (Part 2) booster recipients were included in the safety analysis set. BA.1-monovalent and -bivalent booster vaccines were well-tolerated with no new safety concerns identified. Compared with mRNA-1273, a fourth dose of BA.1-monovalent or -bivalent vaccine elicited superior nAb responses against omicron BA.1 at Month 3, with geometric mean ratios (GMRs) of 1.77  and 1.67 , respectively. Non-inferior  nAb responses against D614G were also demonstrated with GMRs of 0.80  for BA.1-monovalent and 1.11  for -bivalent vaccines.The BA.1 monovalent and bivalent booster vaccines elicited nAb responses against BA.1 that remain superior to mRNA-1273 at 3 months post-booster with no new safety concerns. These results support variant-updated vaccines to protect against evolving SARS-CoV-2.Ivan T. Lee, MD, PhD, Moderna, Inc.: Salary|Moderna, Inc.: Stocks/Bonds Catherine A. Cosgrove, PhD, Novavax: Advisor/Consultant|Novavax: Grant/Research Support|Novavax: Speaker Patrick Moore, MRCGP, AstraZeneca: Advisor/Consultant|AstraZeneca: Grant/Research Support|GSK: Advisor/Consultant|GSK: Grant/Research Support|Janssen: Advisor/Consultant|Janssen: Grant/Research Support|Medicago: Advisor/Consultant|Medicago: Grant/Research Support|Moderna, Inc.: Advisor/Consultant|Moderna, Inc.: Grant/Research Support|MSD: Advisor/Consultant|MSD: Grant/Research Support|Novavax: Advisor/Consultant|Novavax: Grant/Research Support|Sanofi: Advisor/Consultant|Sanofi: Grant/Research Support Philip Kalra, MD, Astellas: Advisor/Consultant|Astellas: Grant/Research Support|AstraZeneca: Advisor/Consultant|AstraZeneca: Grant/Research Support|Bayer: Advisor/Consultant|Bayer: Grant/Research Support|Evotec: Advisor/Consultant|Evotec: Grant/Research Support|Fresenius: Advisor/Consultant|Fresenius: Grant/Research Support|GSK: Advisor/Consultant|GSK: Grant/Research Support|Lilly: Advisor/Consultant|Lilly: Grant/Research Support|Otsuka: Advisor/Consultant|Otsuka: Grant/Research Support|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Pharmacosmos: Advisor/Consultant|Pharmacosmos: Grant/Research Support|Unicyte: Advisor/Consultant|Unicyte: Grant/Research Support|Vifor: Advisor/Consultant|Vifor: Grant/Research Support Paul Dargan, MBBS, Moderna, Inc.: Grant/Research Support Marta Boffito, MD, PhD, FRCP, AstraZeneca: Honoraria|ATEA: Advisor/Consultant|ATEA: Honoraria|Gilead: Advisor/Consultant|Gilead: Grant/Research Support|Gilead: Honoraria|GSK: Advisor/Consultant|GSK: Grant/Research Support|Moderna: Grant/Research Support|MSD: Advisor/Consultant|MSD: Grant/Research Support|MSD: Honoraria|Novavax: Grant/Research Support|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Roche: Advisor/Consultant|Roche: Grant/Research Support|Valneva: Grant/Research Support|ViiV: Advisor/Consultant|ViiV: Grant/Research Support Fiona Burns, PhD, Gilead Sciences Ltd.: Grant/Research Support|Gilead Sciences Ltd.: Speaker Fees Christopher J. A. Duncan, DPhil, MRC: Grant/Research Support|Wellcome Trust: Grant/Research Support David Chadwick, PhD, Gilead Sciences Ltd: Grant/Research Support|GSK: Grant/Research Support|Janssen: Grant/Research Support|Moderna, Inc.: Grant/Research Support|Novavax: Grant/Research Support|ViiV Healthcare: Grant/Research Support Adrian Palfreeman, MBBS, University Hospital of Leicester NHS Trust. - Leicester (United Kingdom): Employee Paul T. Heath, FRCPCH, AstraZeneca: Grant/Research Support|Janssen: Grant/Research Support|Moderna, Inc.: Grant/Research Support|Novavax: Grant/Research Support|Pfizer: Grant/Research Support|Valneva: Grant/Research Support Bethany Girard, Ph.D., Moderna, Inc.: salary|Moderna, Inc.: Stocks/Bonds Kristen Sellers, PhD, Moderna, Inc.: Salary|Moderna, Inc.: Stocks/Bonds Elizabeth de Windt, MPH, Moderna, Inc.: Salary|Moderna, Inc.: Stocks/Bonds Andrea Sutherland, M.D., MPH, Moderna, Inc.: Salary|Moderna, Inc.: Stocks/Bonds LaRee Tracy, PhD, Moderna, Inc.: Salary|Moderna, Inc.: Stocks/Bonds Honghong Zhou, Ph.D., Moderna, Inc.: salary|Moderna, Inc.: Stocks/Bonds Jacqueline Miller, MD, Moderna, Inc.: salary|Moderna, Inc.: Stocks/Bonds Frances Priddy, MD, MPH, Moderna, Inc.: Salary|Moderna, Inc.: Stocks/Bonds Spyros Chalkias, MD, Moderna, Inc.: Salary|Moderna, Inc.: Stocks/Bonds Rituparna Das, M.D., Moderna, Inc.: Salary|Moderna, Inc.: Stocks/Bonds


Investigation of supplement use and knowledge among Japanese elite athletes for the Tokyo 2020 Olympic/Paralympic games and the Beijing 2022 winter Olympic/Paralympic games By Myoenzono K, Yasuda J, Takai E, Shinagawa A, Kaneko N, Yoshizaki T, Namma-Motonaga K, Yoshino M, Kondo E, Nakajima K, Hangai M, Kamahara K, Kamihigashi E, Kusano S and Kamei A (2023). Front. Sports Act. Living 5:1258542. doi: 10.3389/fspor.2023.1258542A Corrigendum on In the published article, references 24 and 39 were incorrectly written. The refences were written as:“24. Nutrition, N. I. O. H. A. The dietary reference intakes.”“39. World Anti-Doping Agency. (2020). Anti-doping rule violations (ADRVs) report.”and should read:https://www.mhlw.go.jp/content/001151422.pdf [Accessed 7 Oct 2023]”“24. Ministry of Health. Dietary Reference Intakes for Japanese. Available: https://www.wada-ama.org/en/resources/anti-doping-stats/anti-doping-rule-violations-adrvs-report#resource-download [Accessed 7 Oct 2023]”“39. World Anti-Doping Agency. (2020). Anti-doping rule violations (ADRVs) report. Available: The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.


RENOIR is a phase 3 randomized, double-blinded, placebo-controlled study evaluating Vaccine Efficacy (VE) to prevent lower respiratory tract illness (LRTI) in adults ≥ 60 years of age during 2 RSV seasons in Northern and Southern Hemisphere countries (NCT05035212). End of RSV Season 1 (EoS1) analysis demonstrated VE of 88.9% for RSV-associated Lower Respiratory Tract Illness (LRTI-RSV) with 3+ symptoms, VE of 65.1% for LRTI-RSV with 2+ symptoms, and VE of 62.2% for all Acute Respiratory Illness (ARI)-RSV events including LRTI-RSV 2+ and 3+ events. We sought to understand the ARI symptom distribution (e.g. upper respiratory versus lower) among all RSV confirmed endpoints, and the characterization of medical diagnoses provided for these endpoints by clinicians.As per study protocol, ARI is an illness involving 1 or more of 7 respiratory illness symptoms lasting more than 1 day: new/increased sore throat, cough, nasal congestion, nasal discharge, wheezing, sputum production, shortness of breath during the RSV season. Participants with ARI symptoms obtain a nasal self-swab within 7 days of onset for RT-PCR testing and undergo virtual or in-person evaluation. Clinical diagnoses are collected at medically attended visits or by investigator assessment. Additional Study Definitions: LRTI is an ARI with at least 2 or 3 signs/symptoms: new or increased cough, wheezing, sputum production, shortness of breath, tachypnea lasting more than 1 day. ARI-RSV and LRTI RSV is an RT-PCR confirmed ARI or LRTI.At EoS1, respiratory symptoms trended lower for cough, sputum production, wheezing, shortness of breath, and tachypnea in RSVpreF recipients compared to placebo recipients. Of these wheezing, shortness of breath, and tachypnea are considered as more severe symptoms. Diagnoses of bronchitis, Influenza-like illness, and pneumonia were less common in RSVpreF recipients compared to placebo recipients.The reduction of more severe LRTI-RSV symptoms and diagnoses amongst all ARI-RSV events in vaccine recipients reflects the higher VE against more severe RSV disease observed in the RENOIR study. The vaccine impacts symptoms that are associated with lower respiratory involvement.Gonzalo Pérez Marc, M.D., GSK: Grant/Research Support|Merck: Grant/Research Support|Moderna: Expert Testimony|Moderna: Grant/Research Support|Pfizer: Grant/Research Support Edward E. Walsh, MD, Icosavax: Advisor/Consultant|Merck: Advisor/Consultant|Merck: Grant/Research Support|Merck: Honoraria|Moderna: Advisor/Consultant|Pfizer: Grant/Research Support Elliot N. DeHaan, MD, Pfizer: Employee|Pfizer: Stocks/Bonds Agnieszka Zareba, MD PhD, Pfizer: Employee|Pfizer: Stocks/Bonds|Pfizer: Stocks/Bonds Qin Jiang, PhD, Pfizer: Employee|Pfizer: Employee|Pfizer: Stocks/Bonds|Pfizer: Stocks/Bonds Kumar Ilangovan, MD, MSPH, MMCi, Pfizer, Inc.: Employee|Pfizer, Inc.: Stocks/Bonds Daniel P. Eiras, MD, MPH, Pfizer, Inc.: Stocks/Bonds Tarek Mikati, MD,MPH, Pfizer: Stocks/Bonds Elena Kalinina, PhD, Pfizer: Pfizer employee|Pfizer: Stocks/Bonds David Cooper, PhD, Pfizer, Inc.: Stocks/Bonds Annaliesa S. Anderson, PhD, Pfizer: Employee|Pfizer: Stocks/Bonds Kena A. Swanson, Ph.D., Pfizer: Employee|Pfizer: Stocks/Bonds William C. Gruber, MD, Pfizer, Inc.: Employee|Pfizer, Inc.: Stocks/Bonds Alejandra C. Gurtman, M.D., Pfizer: Employee|Pfizer: Stocks/Bonds Beate Schmoele-Thoma, MD, Pfizer: Stocks/Bonds


The correct name is: Bewket Yeserah Aynalem. The correct citation is: Desta M, Getaneh T, Aynalem BY, Worku Y, Eshete T. Birhanu MY, et al. (2021) Cervical cancer screening utilization and predictors among eligible women in Ethiopia: A systematic review and meta-analysis. PloS ONE 16(11): e0259339.


Beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations and cefiderocol (FDC) have been recommended for the treatment of carbapenem-resistant Enterobacterales (CRE), but extensive comparisons of these agents are limited. We tested the activity of aztreonam-avibactam (ATM-AVI), ceftazidime-avibactam (CAZ-AVI), meropenem-vaborbactam (MEV), imipenem-relebactam (IR), all BL/BLIs, and FDC against > 500 CRE isolates collected in US hospitals during a 6-year period (2017–2022).A total of 54,576 Enterobacterales (ENT) isolates collected during 2017–2021 were susceptibility (S) tested by reference broth microdilution methods. CRE isolates displayed meropenem and/or imipenem MIC results at > 1 mg/L and were submitted to whole genome sequencing for analysis of resistance mechanisms.The CRE isolates  were mainly KPC producers without metallo-beta-lactamases . Genes encoding MBLs and OXA-48–like enzymes alone were detected among 50 and 12 isolates, respectively. Another 12 isolates carried genes encoding NMC-A and SME. ATM-AVI inhibited 98.4% of the CRE isolates when applying ATM breakpoints for comparison. FDC, CAZ-AVI, MEV, and IR inhibited 94.7%, 89.2%, 86.7%, and 81.9% of the CRE isolates, respectively. Against class A serine-carbapenemase–producing isolates without MBLs, ATM-AVI, CAZ-AVI, FDC, and MEV demonstrated activity > 98.6%. IR inhibited 92.7% of these isolates. Except for ATM-AVI and FDC, other BL/BLI had limited activity against MBLs, ranging from 2.0% S for IR to 16% for MEV against MBL isolates. ATM-AVI inhibited 98.0% of the MBL isolates while FDC inhibited 74.0%. ATM-AVI, CAZ-AVI, IR, FDC, and MEV inhibited 94.5%, 96.7%, 90.1%, 89.0%, and 87.9% of the carbapenemase-negative isolates (n=91), respectively. Among comparators, tigecycline was the most active, inhibiting 94.7% of the CRE isolates; 84.7% of these isolates displayed a colistin intermediate MIC value of ≤ 2 mg/L.The new BL/BLIs and FDC displayed good activity against a large collection of CRE isolates that were mainly KPC producers from US hospitals. Against MBLs, ATM-AVI was the most active agent, followed by FDC.Mariana Castanheira, PhD, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|bioMerieux: Grant/Research Support|Cipla: Grant/Research Support|CorMedix: Grant/Research Support|Entasis: Grant/Research Support|Melinta: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support Joshua Maher, PhD, AbbVie: Grant/Research Support|Affinity Biosensors: Grant/Research Support|AimMax Therapeutics, Inc: Grant/Research Support|Alterity Therapeutics: Grant/Research Support|Amicrobe, Inc: Grant/Research Support|Arietis Pharma: Grant/Research Support|Armata Pharmaceuticals, Inc: Grant/Research Support|Astrellas Pharma, Inc.: Grant/Research Support|Basilea Pharmaceutica AG: Grant/Research Support|Becton Dickinson And Company: Grant/Research Support|bioMerieux, Inc: Grant/Research Support|Boost Biomes: Grant/Research Support|Diamond V: Grant/Research Support|Fedora Pharmaceuticals, Inc: Grant/Research Support|Iterum Therapeutics plc: Grant/Research Support|Johnson & Johnson: Grant/Research Support|Kaleido Biosciences, Inc.: Grant/Research Support|Meiji Seika Pharma Co. Ltd.: Grant/Research Support|National Institutes of Health: Grant/Research Support|Pfizer Inc.: Grant/Research Support|Roche Holding AG: Grant/Research Support|Shionogi Inc.: Grant/Research Support|Summmit Therapeutics, Inc.: Grant/Research Support|Zoetis Inc: Grant/Research Support Katie Simpson, BS, AbbVie: Grant/Research Support Cory Hubler, BS, AbbVie: Grant/Research Support|Shionogi: Grant/Research Support Helio S. Sader, MD, PhD, FIDSA, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|Cipla: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support


The In vitro Activity of Cefiderocol and Comparator Agents Against Pediatric IsolatesP. aeruginosa, 194 Acinetobacter baumannii-calcoaceticus complex (ABC) and 220 S. maltophilia from the USA and Europe were tested for susceptibility (%S) by broth microdilution with cation-adjusted Mueller-Hinton broth (CAMHB). Iron-depleted CAMHB was applied for CFDC. Comparators included newer β-lactam/β-lactamase inhibitor (BL/BLI) combinations ceftazidime-avibactam (CZA), ceftolozane-tazobactam (C/T), imipenem-relebactam (I-R) and meropenem-vaborbactam (MVB) as well as ampicillin/sulbactam (SAM) meropenem (MEM) and colistin (CST). %S was interpreted according to 2023 CLSI & EUCAST breakpoints. Carbapenem non-susceptible (CarbNS) was defined as non-susceptibility to imipenem and MEM.2,249 Enterobacterales (ENT), 707 50/90, 2/4 mg/L; 91.7 %S) was the most active agent against CarbNS ENT. P. aeruginosa susceptibilities to CFDC and BL/BLI combinations were >97.0%. CFDC was the most potent agent against CarbNS P. aeruginosa with MIC50/90 values of 0.12/0.25 mg/L and 100 %S & 98.5 %S per CLSI & EUCAST breakpoints, respectively. ABC susceptibility to CFDC was >97% per CLSI & EUCAST while the susceptibility for MEM was 87.1% (CLSI & EUCAST) and SAM was 80.9% (CLSI). CFDC  displayed better in vitro potency in CarbNS ABC as compared to SAM  and CST . Among pediatric S. maltophilia, CFDC was the most active agent with MIC50/90, 0.06/0.25 and 100 %S per CLSI & EUCAST breakpoints.All agents displayed >96 %S for ENT while CFDC (MICP. aeruginosa, ABC, and S. maltophilia, including CarbNS subsets for which treatment options are limited. These data suggest CFDC may be a valuable treatment for serious Gram-negative infections in pediatric patients.CFDC was a highly active β-lactam against contemporary pediatric isolates of Enterobacterales, Sean T. Nguyen, PharmD, Shionogi: Employee|Shionogi, Inc: Employee Boudewijn L. DeJonge, PhD, Shionogi Inc.: Employee Jason J. Bryowsky, PharmD, MS, Shionogi Inc.: Employee Anne Henriksen, PhD, Shionogi: Employee Christopher M. Longshaw, PhD, Shionogi BV: Employee Joshua Maher, PhD, AbbVie: Grant/Research Support|Affinity Biosensors: Grant/Research Support|AimMax Therapeutics, Inc: Grant/Research Support|Alterity Therapeutics: Grant/Research Support|Amicrobe, Inc: Grant/Research Support|Arietis Pharma: Grant/Research Support|Armata Pharmaceuticals, Inc: Grant/Research Support|Astrellas Pharma, Inc.: Grant/Research Support|Basilea Pharmaceutica AG: Grant/Research Support|Becton Dickinson And Company: Grant/Research Support|bioMerieux, Inc: Grant/Research Support|Boost Biomes: Grant/Research Support|Diamond V: Grant/Research Support|Fedora Pharmaceuticals, Inc: Grant/Research Support|Iterum Therapeutics plc: Grant/Research Support|Johnson & Johnson: Grant/Research Support|Kaleido Biosciences, Inc.: Grant/Research Support|Meiji Seika Pharma Co. Ltd.: Grant/Research Support|National Institutes of Health: Grant/Research Support|Pfizer Inc.: Grant/Research Support|Roche Holding AG: Grant/Research Support|Shionogi Inc.: Grant/Research Support|Summmit Therapeutics, Inc.: Grant/Research Support|Zoetis Inc: Grant/Research Support Rodrigo E. Mendes, PhD, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|Cipla: Grant/Research Support|Entasis: Grant/Research Support|GSK: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support Miki Takemura, n/a, Shionogi & Co., Ltd.: Stocks/Bonds Yoshinori Yamano, PhD, Shionogi HQ: Employee


Testicular tissue cryopreservation for fertility preservation in prepubertal and adolescent boys: A 6 year experience from a Swiss multi-center network By Moussaoui D, Surbone A, Adam C, Diesch-Furlanetto T, Girardin C, Bénard J, Vidal I, Bernard F, Busiah K, Bouthors T, Primi M-P, Ansari M, Vulliemoz N and Gumy-Pause F. (2022) Front. Pediatr. 10:909000. doi: 10.3389/fped.2022.909000An Erratum on An omission to the funding section of the original article was made in error. The following sentence has been added: “Open access funding was provided by the University of Geneva”.The original version of this article has been updated.


Since late December 2021, the COVID-19 Omicron variant has been the predominant variant in the US. While considered less severe than previous variants, the burden of severe COVID-19 remains significant, especially in patients with high-risk underlying conditions. Underutilization of outpatient therapeutics has been reported in this population. The objective of this study was to assess the uptake of outpatient COVID-19 therapeutics 30 days prior to COVID-19 hospitalization during the Omicron period, among those high-risk for hospitalization based on CDC-defined criteria.Table 1) in the 30 days prior to hospital admission was assessed by death, age, number of high-risk conditions, and immunocompromised status.Patients with ≥1 inpatient hospitalization, a primary diagnosis of COVID-19 (ICD10 U07.1) and ≥ 1 CDC-defined high-risk condition were identified using Optum's de-Identified Clinformatics® Data Mart Database Date of Death claims data from 01/01/22-11/30/22. Death within 1 calendar month after hospitalization was used as a proxy for inpatient death, due to database limitations. Receipt of a COVID-19 outpatient therapeutic  and mostly female (51.9%). Patients with death within 1 calendar month were older (79.7 vs. 74.9 years) and more often male (54.1% vs. 46.9%) than those without. Patients were majority white (68.2%), regardless of death. The most common high-risk conditions at hospitalization were hypertension (88.2%), advanced age , and heart conditions (78.4%). A higher proportion of the most common conditions were observed in hospitalizations with death within 1 calendar month. Overall, 40,463 (94.2%) of high-risk patients had not received COVID-19 outpatient treatment within 30 days prior to hospitalization, of which 6,886 (17.0%) died within 1 calendar month. Percentage of patients treated with COVID-19 outpatient treatments within 30-days prior to hospitalization by key high-risk stratificationsThere was low uptake of COVID-19 outpatient treatment pre-hospitalization in patients high-risk for COVID-19 hospitalization, highlighting the persistent burden of hospitalization and death during the Omicron period among this population.Amie Scott, MPH, Pfizer, Inc: Employee|Pfizer, Inc: Stocks/Bonds Laura A. Puzniak, PhD. MPH, Pfizer, Inc.: Employee|Pfizer, Inc.: Stocks/Bonds Michael V. Murphy, BA, Bellus Health: Advisor/Consultant|Boston Scientific: Employee|Boston Scientific: Stocks/Bonds|EMD Serono: Advisor/Consultant|Pfizer: Advisor/Consultant|Sanofi: Advisor/Consultant|Travere Therapeutics: Advisor/Consultant Darrin W. Benjumea, MPH, Akebia Therapeutics: Advisor/Consultant|Arvinas: Advisor/Consultant|Bellerophon Therapeutics: Stocks/Bonds|Bellus Health: Advisor/Consultant|Genesis Research, LLC: Employee|Novartis: Stocks/Bonds|Pfizer Inc.: Stocks/Bonds|Regeneron: Advisor/Consultant|Regeneron: Stocks/Bonds Andrew Rava, MPH, AbbVie: Advisor/Consultant|Janssen: Advisor/Consultant|Novartis: Advisor/Consultant|Pfizer, Inc.: Advisor/Consultant|Travere Therapeutics, Inc.: Advisor/Consultant Michael Benigno, MA, Pfizer: Employee|Pfizer: Stocks/Bonds Kristen E. Allen, MPH, Pfizer, Inc.: Employee|Pfizer, Inc.: Stocks/Bonds Richard Stanford, PharmD, MS, Pfizer: Advisor/Consultant Fadi Manuel, PharmD, Pfizer: Medical Writing Ashley S. Cha-Silva, PharmD, MS, Pfizer Inc.: Employee|Pfizer Inc.: Stocks/Bonds Maya Reimbaeva, MS, Pfizer, Inc.: Employee|Pfizer, Inc.: Stocks/Bonds Florin Draica, MD, Pfizer Inc.: Honoraria|Pfizer Inc.: Stocks/Bonds


Correction: BMC Cancer 23, 117 (2023)10.1186/s12885-022-10465-yFollowing publication of the original article , the autXia He, hexiabm@163.com; Yong Xu, yxu4696@njmu.edu.cn; Lirong Wu, wulirong126@126.comThe author group in this correction article has been updated and the original article  has been


Clostridioides difficile infections increasingly occur among persons who are diagnosed and receive care in the outpatient setting. We explored the impact of outpatient C. difficile infection (oCDI) on patients’ healthcare-related quality of life (HRQoL).We conducted this prospective study of adults aged ≥ 50 years within the Kaiser Permanente Southern California (KPSC) and Northwest (KPNW) healthcare delivery systems. We identified and recruited individuals with oCDI, defined as laboratory-confirmed CDI with no hospitalization on or in 7 days after diagnosis. To assess HRQoL associated with oCDI, we administered the Cdiff32, a CDI-specific HRQoL questionnaire, shortly after oCDI diagnosis. We also administered the EQ-5D-5L, a generic HRQoL questionnaire, at baseline and approximately 60 days after oCDI to collect Visual Analog Scales (VAS) and Indices pre-infection, on the worst day of illness, and 60 days after diagnosis.pretty or very bad quality of life over the past week and 80 (38%) thought their oCDI made their health condition(s) worse. Within the EQ-5D-5L, 118 (55%) reported having moderate, severe, or complete inability to complete daily activities during the worst day of illness, compared to 20% pre-infection. Cases reported a median pre-infection VAS of 80.0, compared with 44.5 on the worst day of illness (p< 0.0001 vs pre-infection) and 80.0 at 60-days of follow up . Cases also reported median Index values of 0.9 pre-infection, 0.6 on worst day of illness (p< 0.0001 vs pre-infection), and 0.9 at 60 days of follow-up (p< 0.0001 vs worst day and p=0.0081 vs pre-infection).Our study included 213 cases. Most were female 143 (67%), 77 (36%) were 60-69 years of age, and 167 (78%) reported no prior CDI. From the CDiff32, 77 (36%) reported Even when managed within the outpatient setting, patients experienced a significant reduction in HRQoL during their CDI episode.Mark A. Schmidt, PhD, MPH, Intercept Pharmaceuticals: Grant/Research Support|Pfizer: Grant/Research Support|Vir Biotechnology: Grant/Research Support Jennifer L. Kuntz, MS, PhD, Pfizer: Grant/Research Support Fredrick J. Angulo, DVM, PhD, Pfizer Vaccines: Employee|Pfizer Vaccines: Employee|Pfizer Vaccines: Stocks/Bonds|Pfizer Vaccines: Stocks/Bonds Holly Yu, MSPH, Pfizer, Inc,: employee of Pfizer, Inc|Pfizer, Inc,: Stocks/Bonds Elisa Gonzalez, MPH, Pfizer: Stocks/Bonds Joann M. Zamparo, MPH, Pfizer Inc.: Full Time Employee|Pfizer Inc.: Stocks/Bonds Ana Florea, PhD MPH, Gilead: Grant/Research Support|GlaxoSmithKline: Grant/Research Support|Moderna: Grant/Research Support|Pfizer: Grant/Research Support Sara Y. Tartof, PhD MPH, Genentech: Grant/Research Support|GSK: Grant/Research Support|Pfizer: Grant/Research Support|SPERO: Grant/Research Support


Pages 1014 and 1016. The list of authors has been updated to includePaul G. Wyatt, whose information is as follows:Paul G.Wyatt – Drug Discovery Unit,Wellcome Centre for Anti-Infectives Research, School of Life Sciences,University of Dundee, Dundee DD1 5EH, U.K.; orcid.org/0000-0002-0397-245X


The fifth author’s name is misspelled. The correct name is Paolo Korwin Krukowski. The correct citation is:https://doi.org/10.1371/journal.pgen.1010766Martignago D, da Silveira Falavigna V, Lombardi A, Gao H, Korwin Krukowski P, Galbiati M, et al. (2023) The bZIP transcription factor AREB3 mediates FT signalling and floral transition at the Arabidopsis shoot apical meristem. PLoS Genet 19(5): e1010766.


The correct name is: Khairul Adzfa Radzun. The correct citation is: Scott AE, Timms AR, Connerton PL, Loc Carrillo C, Radzun KA, Connerton IF (2007) Genome Dynamics of Campylobacter jejuni in Response to Bacteriophage Predation. PLoS Pathog 3(8): e119.


Corrigendum on:The prevalence of xerostomia among e-cigarette or combustible tobacco users: A systematic review and meta-analysisBy Xingtong Guo, Lili Hou, Xuepei Peng, Fuyou TangTobacco Induced Diseases, Volume 21, Issue February, Pages 1–11, Publish date: 9 February 2023https://doi.org/10.18332/tid/156676DOI: In the originally published version of the article, on pages 1, 5, and 7, the expression 95% CI: 21–17 should read 95% CI: 21–27. This is corrected also online.


Oecobius Lucas, 1846 is the largest genus of the family Oecobiidae Blackwall, 1862, five of which are known from China. Since Oceobiusprzewalskyi was described by Hu & Li in 1987, no males of this species have ever been reported.With 90 described species, the genus Oceobiusprzewalskyi is described for the first time, based on the specimens collected in Tibet Autonomous Region. Morphological description and illustrations are given.The male of  Oecobius Lucas, 1846 is distributed in Asia, Europe, Africa, North and South America with 90 species, five of them recorded in China: O.cellariorum , O.marathaus Tikader, 1962, O.nadiae , O.navus Blackwall, 1859 and O.przewalskyi Hu & Li, 1987 , which build sparse webs in the corners or gaps of houses and hide themselves in webs   . RecentlThe specimens examined in this study were deposited in the Centre for Behavioural Ecology and Evolution, College of Life Sciences, Hubei University in Wuhan. Specimens were examined using an OLYMPUS SZX7 stereomicroscope. Photographs were taken with a LEICA M205 C stereomicroscope and OLYMPUS SXZ16 microscope and final multifocal images were produced with Helicon Focus (Version 7.7.0). The male palp was examined and photographed after dissection. The epigyne was examined after being dissected from the spider’s body. The epigyne was removed and treated in a warmed 0.1 mg/ml Protease K solution before study. All morphological measurements were calculated using a Leica M205 C stereomicroscope. Eye diameters were taken at the widest point. Leg measurements were given as total length of leg . All measurements were in millimetres (mm).ALE anterior lateral eyes, AME anterior median eyes, CD copulatory duct, CO copulatory opening, E embolus, EA embolic apophysis, I, II, III, IV legs I to IV, PLE posterior lateral eyes, PME posterior median eyes, Sp spermatheca, TA tegular apophysis, TL I tegular lobe I.Morphological terminology follows Hu & Li, 1987A7F0A249-EF01-584B-B700-056F80A7E42Fhttps://www.gbif.org/species/2162478Oecobiusprzewalskyi Hu & Li, 1987 in Type status:Holotype. Occurrence: occurrenceRemarks: not examined; recordedBy: Aihua Li; individualCount: 1; sex: female; lifeStage: adult; Location: continent: Asia; country: China; countryCode: China/CN; stateProvince: Tibet; verbatimLocality: Shigatse; verbatimElevation: 3800 m; Event: year: 1985; month: 7; day: 31Type status:Paratype. Occurrence: occurrenceRemarks: not examined; recordedBy: Aihua Li; individualCount: 4; sex: 4 females; lifeStage: adult; Location: continent: Asia; country: China; countryCode: China/CN; stateProvince: Tibet; verbatimLocality: Shigatse; verbatimElevation: 3800 m; Event: year: 1985; month: 7; day: 31Type status:Other material. Occurrence: recordedBy: Fengxiang Liu; individualCount: 2; sex: 1 male, 1 female; lifeStage: adult; Location: continent: Asia; country: China; countryCode: China/CN; stateProvince: Tibet; verbatimLocality: Shigatse, Mountain of Tashilhunpo Monastery; verbatimElevation: 3836 m; verbatimLatitude: 29.265392°N; verbatimLongitude: 88.871941°E; Event: year: 2002; month: 9; day: 6Male: Total length 2.18. Carapace 0.80 long, 0.93 wide. Abdomen 1.49 long, 0.95 wide. Diameters of eyes: AME 0.04, ALE 0.06, PME 0.05, PLE 0.06. Interdistances of eyes: AME‒AME 0.04, AME‒ALE 0.03, PME‒PME 0.08, PME‒PLE 0.01, AME‒PME 0.06, ALE‒PLE 0.02. Eyes white with black rings, except PME. Carapace light yellowish-brown with black margin, except clypeal projection, fovea black. Palps, chelicerae, labium and legs pale brown without marks. Measurements of legs: I 2.81 , II 3.00 , III 3.20 , IV 3.30 . Leg formula: IV-III-II-I. Abdomen dorsally yellowish-brown with white irregular marks, cardiac mark light brown. Abdomen ventrally light yellow with few white irregular marks  short and small, located in the median of bulb in ventral view and bent prolaterally; tegular apophysis (TA) four-branched, upper branch strongly sclerotic, with curled end and an outside tip, median branch small and rounded, two lower branches horn-like; embolic apophysis (EA) point to upward side of bulb and with serrated margin, dorsal embolic apophysis (EA) covered; tegular lobe I (TL I) large and thick, with two apophyses, upper apophysis pointed and lower apophysis rounded Fig. A‒C.Female: Total length 3.40. Carapace 1.03 long, 1.20 wide. Abdomen 2.57 long, 1.59 wide. Diameters of eyes: AME 0.08, ALE 0.07, PME 0.06, PLE 0.06. Interdistances of eyes: AME‒AME 0.10, AME‒ALE 0.04, PME‒PME 0.10, PME‒PLE 0.02, AME‒PME 0.01, ALE‒PLE 0.02. Measurements of legs: I 4.05 , II 4.44 , III 4.41 , IV 4.58 . Leg formula: IV-II-III-I. Colouration as in male, except cardiac mark dark brown, abdomen ventrally light yellow with white irregular marks  located in posterior side; copulatory ducts (CD) visible in ventral view; vulva with wrinkles in posterior side, left copulatory duct (CD) pointing to 1 o'clock; spermathecae (Sp) oval and membranous, located in anterior side Fig. .Oecobiusprzewalskyi can be distinguished from other Oecobius species by 1. tegular apophysis (TA) four-branched, upper branch with curled end and an outside tip, median branch small and rounded, two lower branches horn-like; 2. embolic apophysis (EA) with serrated margin; 3. tegular lobe I (TL I) thick, with two apophyses, upper apophysis pointed and lower apophysis rounded  visible in ventral view, left copulatory duct (CD) pointing to 1 o'clock  Fig. .O.przewalskyi, the left copulatory duct (CD) which is pointing to 1 o'clock and the two oval spermathecae (Sp) shown in the original illustrations (Fig. Although we did not examine the type specimens of ons Fig.  leave no


Respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus type 3 (PIV3) are common respiratory illnesses in children. Two investigational vaccines, mRNA-1345, encoding the RSV prefusion stabilized F (preF) glycoprotein, and mRNA-1653, encoding the hMPV and PIV3 F glycoproteins, are in clinical trials.Two phase 1, randomized, observer-blind, placebo-controlled trials in children aged 12-59 months assessed safety and immunogenicity of mRNA-1345 (NCT04528719) and mRNA-1653 (NCT04144348). In the mRNA-1345 trial, RSV-seropositive children (N=46) were randomized to receive 3 doses of mRNA-1345 (15 µg or 30 µg) or placebo 2 months apart. In the mRNA-1653 trial, hMPV- and PIV3-seropositive children (N=27) were randomized to receive 2 doses of mRNA-1653 (10 µg or 30 µg) or placebo 2 months apart. Interim data through Month (M) 5 for mRNA-1345 and M3 for mRNA-1653 are reported.Fig 1A and 2A). One mRNA-1653 injection boosted hMPV and PIV3 nAb titers  and preF and postF bAb concentrations ; a second injection did not further increase antibody levels . In both trials, bAb responses were generally preF biased.mRNA-1345 and mRNA-1653 were well-tolerated. The most frequently reported solicited local adverse reaction (AR) was tenderness at injection site ; solicited systemic ARs  were mostly grade 1/2. One mRNA-1345 injection boosted RSV neutralizing antibody (nAb) titers  and RSV preF and postF binding antibody (bAb) concentrations ; additional injections did not further elevate antibody levels (In seropositive children aged 12-59 months, mRNA-1345 and mRNA-1653 were well-tolerated and boosted RSV and hMPV plus PIV3 antibodies, respectively, supporting their continued development and that of a combination RSV and hMPV vaccine.Matthew D. Snape, MBBS, MD, FRCPCH, FPM, FMedSci, Moderna Biotech UK, Inc.,: Employee|Moderna Biotech UK, Inc.,: Stocks/Bonds Sabine Schnyder Ghamloush, MD, Moderna, Inc.: Employee|Moderna, Inc.: Stocks/Bonds Grace L. Chen, MD, MPH, Moderna, Inc.: Employee|Moderna, Inc.: Stocks/Bonds Rakesh Dhar, MD, Moderna, Inc.: Employee|Moderna, Inc.: Stocks/Bonds Runa Mithani, PharmD, Moderna, Inc: Employee|Moderna, Inc: Stocks/Bonds Vinicius Righi, PharmD, MBA, Moderna, Inc.: Employee|Moderna, Inc.: Stocks/Bonds Louie Morsy, BS, Moderna, Inc.: Employee|Moderna, Inc.: Stocks/Bonds Archana Kapoor, PhD, Moderna, Inc.: Employee|Moderna, Inc.: Stocks/Bonds Bethany Girard, Ph.D., Moderna, Inc.: salary|Moderna, Inc.: Stocks/Bonds Laila El Asmar, PhD, Moderna, Inc.: Employee|Moderna, Inc.: Stocks/Bonds Christine A. Shaw, PhD, Moderna, Inc.: Employee|Moderna, Inc.: Stocks/Bonds


Correction: Cell Commun Signal 21, 297 (2023)https://doi.org/10.1186/s12964-023-01329-4Following publication of the original article , the autThe funding note should read: This project was funded by the Austrian Science Fund (FWF), projects P 34867 , P 33073 (S.S.), and the PhD Program Molecular, Cellular and Clinical Allergology DK W1248-B30 ; the Government of Lower Austria Danube Allergy Research Cluster ; BioTechMed-Graz Flagship Project Secretome (S.S.); the OeAD WTZ grants CZ 06/2020 (A.S. and I.S.), PL 03/2022 (I.S.), RS 08/2022 (A.S. and I.S.), PL 04/2019 (I.S.), and CZ 07/2023 (I.S. and J.H.); and by European Union through MSCA-PF project LactoVES (Grant Agreement no. 101066450 (A.R.).Additional file 1 has also been correctly linked to the original article.The original article has been


The correct name is: Benedetta Heimler. The correct citation is: Buchs G, Heimler B, Kerem M, Maidenbaum S, Braun L, Amedi A (2021) A self-training program for sensory substitution devices. PLoS ONE 16(4): e0250281.


Correction: Journal of Translational Medicine (2023) 21:449https://doi.org/10.1186/s12967-023-04292-3First name: MaysalounLast name: Merhi7Department of Chemistry, College of Sciences, United Arab Emirates University, Al-Ain, United Arab EmiratesFollowing publication of the original article , we have


Drosophila, and mice. eLife10:e65092. doi: 10.7554/eLife.65092. Abrams NJ, Tan FH, Li Y, Basinger T, Heithe ML, Sarma A, Lee IT, Condiotte ZJ, Raffiee M, Dabiri JO, Gold DA, Goentoro L. 2021. A conserved strategy for inducing appendage regeneration in moon jellyfish, Published 7 December 2021There was an error in the Materials and methods of this article. This error (which was in the fourth sentence of the section "Regeneration experiments") has now been corrected.Drosophila were allocated randomly to vials with standard lab fly food (control) or standard lab fly food mixed with 1.7 mM L-Leucine (Sigma-Aldrich L8000), 1.7 mM L-Glutamine (Sigma-Aldrich G3126), and 33 μg/ml insulin .Corrected text: Recovering Drosophila were allocated randomly to vials with standard lab fly food (control) or standard lab fly food mixed with 5 mM L-Leucine (Sigma-Aldrich L8000), 5 mM L-Glutamine (Sigma-Aldrich G3126), and 0.1 mg/ml insulin .Original text: Recovering The article has been corrected accordingly.


Correction: Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine (2023) 31:4010.1186/s13049-023-01108-7The Reference list of the original article  unfortunThe correct reference should read: Tao W, Jie C, Yujiang Z, et al. Preliminary investigation of building damage in Hatay under February 6, 2023 Turkey earthquakes. Earthq Eng Eng Vib. Published online July 4, 2023. doi:10.1007/s11803-023-2201-0.The original article has already been revised.


Nature Communications 10.1038/s41467-023-42088-7, published online 07 October 2023Correction to: In this article Thomas E. Cope, Timothy D. Griffiths, Matthew A. Howard III and Christopher I. Petkov should have been denoted as equally contributing joint senior authors. The original article has been corrected.


The correct name is: Sunisa Chaiklieng. The correct citation is: Poochada W, Chaiklieng S (2022) Self-reported musculoskeletal disorders questionnaire for agriculturists: An online self-assessment tool development. PLoS ONE 17(12): e0277548.


Article title: WRH-2412 alleviates the progression of hepatocellular carcinoma through regulation of TGF-β/β-catenin/α-SMA pathwayAuthors: Mohammed A. F. Elewa, Wagdy M. Eldehna, Ahmed M. E. Hamdan, Samraa H. Abd El-kawi, Asmaa M. El-Kalaawy, Taghreed Majrashi, Reham F. Barghash, Hatem A. Abdel-Azizb, Khalid S. Hashem, Mohammed M. Al-GayyarJournal:Journal of Enzyme Inhibition and Medicinal ChemistryBibliometrics: Volume 38, Number 1DOI:https://doi.org/10.1080/14756366.2023.2185761When the article has been previously published, an incorrect version of the figures were included. The correct version of the figures is as follows:The authors are not responsible for the errors and the online version of this paper has been corrected.


Camptoscaphiella Caporiacco, 1934 is a small genus of oonopid spiders that currently contains 20 species, of which five have been recorded in Yunnan, China.Camptoscaphiella, C.hudie Tong & Yang, sp. nov. , C.yinglefeng Tong & Yang, sp. nov.  and C.yujufeng Tong & Yang, sp. nov.  are described from Yunnan, China. Descriptions, diagnoses and photographs are provided.Three new species of  Oonopidae is a diverse spider family with 1932 extant described species in 115 genera. The genus Camptoscaphiella Caporiacco, 1934 is mainly distributed in tropical and subtropical montane regions of Asia, mostly within the Himalayan Plateau. Only two species have been recorded in the Paciﬁc island of New Caledonia  mounted on an Olympus BX51 compound microscope. Scanning electron microscope images (SEM) were taken under high vacuum with a Hitachi S-4800, specimens were air-dried and sputter-coated using IXRF SYSTEMS. All measurements were taken using an Olympus BX51 compound microscope and are given in millimetres.Type material is deposited in Shenyang Normal University (SYNU) in Liaoning, China.The following abbreviations are used in the text and figures: ALE = anterior lateral eyes; ap = apodemes; as = anterior sclerite; cd = copulatory duct; PLE = posterior lateral eyes; PME = posterior median eyes; psr = posterior scutal ridge; rlf = retrolateral fold; spr = semicircular, prolateral rim; tmp = triangular median plate; tss = triangular sclerotised structure; va = ventral appendices; vp = ventral process.Tong & Yangsp. nov.6DD015E1-FB24-5F53-B5F7-5ACED40D90774BB6BDF4-09AB-4364-BC98-0CFEACB97393Type status:Holotype. Occurrence: recordedBy: Rong Huang & Depeng Xu; individualID: SYNU-670; individualCount: 1; sex: female; lifeStage: adult; preparations: whole animal; occurrenceID: 8325A7FC-AB10-5A60-AE6B-5DFE1A6C48C3; Taxon: order: Araneae; family: Oonopidae; genus: Camptoscaphiella; specificEpithet: hudie; scientificNameAuthorship: Tong & Yang; Location: country: China; stateProvince: Yunnan; county: Dali City; locality: Cangshan Mountain, post-fire forest in 2008; verbatimCoordinates: 25°38′52″N, 100°07′15″E; Identification: identifiedBy: Yanfeng Tong; Event: eventDate: 15 November 2008Female (Holotype). Body: pale yellow, abdomen and legs yellowish-white; habitus as in Fig. Male: unknown.Camptoscaphiellapanchthar Baehr, 2010, but can be distinguished by the very small dorsal scutum of abdomen . Body: yellow, abdomen ventrally and laterally paler, whitish; habitus as in Fig. Female SYNU-694). Body: habitus as in Fig. . Body: hCamptoscaphiellatuberans Tong & Li, 2007, but can be distinguished by the cluster of black, strong setae on the labium . Body: pale yellow, abdomen paler; habitus as in Fig. Female: unknown.Camptoscaphiellayinglefeng sp. nov., but can be distinguished by the dorsal scutum ca. 1/3 of abdomen width  and Camptoscaphiellayujufeng sp. nov.  were collected from the same locality, Cangshan Mountain. The dorsal abdominal scutum of C.hudie is very small and narrow, quite different from that of C.yujufeng (compare Fig.